

Iris Grossman, Ph.D.

Chief Scientific Officer
CAMP4 Therapeutics

As Chief Scientific Officer (CSO) at CAMP4 Therapeutics, Dr. Iris Grossman is responsible for leading the company's mission to discover, and therapeutically harness, mechanisms by which every gene in the human body responds to its environment through signaling, integrating multi-dimensional experimental data into CAMP4's proprietary Gene Circuitry Platform. Under her direction, CAMP4 uses this platform to rapidly predict and validate druggable targets that control gene expression affecting a broad spectrum of diseases. Dr. Grossman also oversees the advancement of CAMP4's drug pipeline and all scientific partnerships.

Dr. Grossman's industry experience includes management roles at both large biopharmaceutical companies (such as GlaxoSmithKline and Teva Pharmaceuticals) and start-ups (such as Zinfandel Pharmaceuticals), as well as consultancy firms (such as Cabernet Pharmaceuticals). She has focused on leveraging genomic biomarkers, pharmacometrics and eHealth to augment the discovery, development and lifecycle management of biopharmaceutical assets. Prior to joining CAMP4, Dr. Grossman held roles of increasing responsibility at Teva, most recently serving as VP, Head of the Early Stage Clinical Development. In this role, she was responsible for defining and implementing the global personalized medicine and analytics strategy for Teva R&D.

In addition to serving as CSO at CAMP4, Dr. Grossman is co-founder and CEO of GROSS Advantage (previously IsraGene), a consultancy firm that advises clients on biomarker and digital health innovation in R&D and real-world settings. Dr. Grossman is also a member of the Scientific Advisory Board of BC Platforms and a Steering Committee member of Tipa, Maccabi Healthcare Services' biobank.

Dr. Grossman earned a Bachelor of Science degree from the Technion – Israel Institute of Technology and a PhD in medicine and pharmacogenetics also from the Technion, co-mentored with the Weizmann Institute of Science. She completed a post-doctoral fellowship at Duke University.